The registration to the symposium is free of charge and is offered on a first come, first serve basis to the first 100 registered participants.
To view the program and pre-register for the European Union Funding for Alzheimer Disease - The ADIT Project Official Pre-AD/PD Symposium taking place on Tuesday, March 10, 2009 from 09:00 - 18:00 click here:
http://www.aditproject.org/registration.html
Siena Biotech S.p.A.
Strada del Petriccio e Belriguardo, 35
53100 Siena - ITALY
www.sienabiotech.it
Siena Biotech is an integrated drug discovery company with a focus on neurodegenerative and neuroproliferative diseases. The company’s aim is to increase understanding of the pathophysiology of disease and to exploit this knowledge for development of efficacious new medicines. To this end a comprehensive drug discovery platform - spanning target and lead discovery to phase II clinical studies – has been established by implementing the most advanced technologies. A well-balanced project portfolio in the areas of Alzheimer disease, Huntington disease and glioblastoma has been developed and the most advanced project of Siena Biotech is currently in clinical trials.
ADIT is one of three large collaborative research projects in Alzheimer disease (AD) funded by the European Union’s Framework Programme 6 (FP6). Its partner consortium comprises centers of excellence from six different EU member countries. The project capitalizes on the most widely accepted view on the etiology of AD, the amyloidogenic hypothesis and aims at unravelling the patho-mechanism of the disease in order to identify target proteins and novel chemical entities acting on them as potential drug candidates for AD therapy. A validated neuronal model system of Aß toxicity, established transcriptomics and proteomics methodologies and sophisticated bioinformatics tools are being used in order to identify proteins causally involved in Aß-mediated neurodegeneration. An efficient drug discovery process - combining stringent target validation based on in vitro, in vivo and ex vivo approaches and straight forward lead discovery capacities including high-throughput screening, chemoinformatics and medicinal chemistry - is being employed to identify and progress potential drug candidates towards development.
The aim of this symposium is to highlight ADIT results obtained during four years of collaborative research and to present them in the broader context of AD and drug discovery for CNS disorders. To this end, leading experts from academia, industry and EU Directorate for health will be brought together to illuminate important aspects for contemporary AD research which will be complemented by presentations of major ADIT achievements by the partner consortium.